Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics.

Home, Philip D; McCrimmon, Rory J; Rosenstock, Julio; Blüher, Matthias; Pegelow, Katrin; Melas-Melt, Lydie; Djaballah, Khier; Giorgino, Francesco

Home, Philip D; McCrimmon, Rory J; Rosenstock, Julio; Blüher, Matthias; Pegelow, Katrin; Melas-Melt, Lydie; Djaballah, Khier; Giorgino, Francesco.

Affiliation

Home PD; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
McCrimmon RJ; Division of Systems Medicine, School of Medicine, University of Dundee, Dundee, UK.
Rosenstock J; Velocity Clinical Research at Medical City, Dallas, Texas, USA.
Blüher M; Department of Medicine, University of Leipzig, Leipzig, Germany.
Pegelow K; Sanofi, Berlin, Germany.
Melas-Melt L; IVIDATA Life Sciences, Levallois-Perret, France.
Djaballah K; Sanofi, Paris, France.
Giorgino F; Department of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy.

Diabetes Obes Metab ; 25(3): 656-663, 2023 03.

Article de En | MEDLINE | ID: mdl-36309941

Sujet(s)
Mots clés

GLP-1 analogue; basal insulin; glycaemic control; hypoglycaemia; iGlarLixi; insulin therapy; randomized trial; type 2 diabetes

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Diabète de type 2 / Hypoglycémie Type d'étude: Diagnostic_studies Limites: Humans Langue: En Journal: Diabetes Obes Metab Sujet du journal: ENDOCRINOLOGIA / METABOLISMO Année: 2023 Type de document: Article Pays d'affiliation: Royaume-Uni Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google